Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease

Summary

The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD). A secondary objective is to describe the long term progression of Alzheimer's symptoms in patients treated by 4 mg/day of SR57667B.

Timeline

Start

2004-03

Primary completion

2006-11

Completion

2006-11

Drugs

Indications